SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10322	Companies
213990	Keywords
143687	Articles
113275	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/03/2024 at 22:15, 1 year 10 months ago

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
Sarclisa in combo with VRd significantly enhances progression-free survival in newly diagnosed transplant-ineligible multiple myeloma in phase 3 study at ASCO. Full data published in NEJM

Multiple Myeloma Phase 3 Sarclisa Progression-free Survival VRd
BRIEF

published on 05/31/2024 at 12:05, 1 year 10 months ago

Sanofi Launches 2024 Global Employee Stock Purchase Plan

Financial Investment Sanofi Employee Stock Purchase Plan Action 2024 Global Participation
PRESS RELEASE

published on 05/31/2024 at 12:00, 1 year 10 months ago

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan, Action 2024, offering discounted shares to 80,000 employees in 56 countries. CEO Paul Hudson affirms commitment to employee participation and company growth

Company Growth Sanofi Employee Stock Purchase Plan Action 2024 Employee Shareholders
BRIEF

published on 05/31/2024 at 07:10, 1 year 10 months ago

CHMP recommends approval of Dupixent in the EU for the treatment of patients with COPD

Sanofi COPD Dupixent CHMP Supply
PRESS RELEASE

published on 05/31/2024 at 07:05, 1 year 10 months ago

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
European Medicines Agency's CHMP recommends Dupixent for EU approval to treat uncontrolled COPD with raised blood eosinophils. If approved, it would be the first targeted therapy for COPD in the EU

Dupixent CHMP EU Approval COPD Treatment Type 2 Inflammation
BRIEF

published on 05/30/2024 at 15:06, 1 year 10 months ago

Sanofi Completes Acquisition of Inhibrx, Inc.

Acquisition Sanofi Rare Diseases Inhibrx SAR447537
PRESS RELEASE

published on 05/30/2024 at 15:01, 1 year 10 months ago

Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB

Acquisition Nasdaq Sanofi Inhibrx SAR447537
BRIEF

published on 05/27/2024 at 07:05, 1 year 11 months ago

FDA Grants Priority Review to Sarclisa for Treatment of Multiple Myeloma

FDA Sanofi Multiple Myeloma Sarclisa Chemotherapy
BRIEF

published on 05/21/2024 at 07:35, 1 year 11 months ago

Sanofi, Formation Bio, and OpenAI Announce AI Collaboration

Collaboration AI Drug Development Sanofi OpenAI Formation Bio
PRESS RELEASE

published on 05/21/2024 at 07:30, 1 year 11 months ago

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio, and OpenAI collaborate to accelerate drug development with AI-powered software. The partnership aims to bring new medicines more efficiently

Collaboration Drug Development Sanofi OpenAI Formation Bio

Accesswire

Published on 04/30/2026 at 01:35, 3 hours 29 minutes ago

Kalo Gold Provides Update on High-Resolution Airborne Magnetic Survey at Vatu Aurum Project, Fiji
Published on 04/30/2026 at 01:15, 3 hours 49 minutes ago

Credissential Announces Shares Consolidation
Published on 04/30/2026 at 00:49, 4 hours 15 minutes ago

Fourth Quarter and Year-End 2025 Results
Published on 04/30/2026 at 00:00, 5 hours 4 minutes ago

Redwood AI CEO Highlights Role of its AI Technology Within Aidos-Led B.C. Government's Track and Trace Pilot Program on Conversations That Matter TV Series, Featured in the Vancouver Sun
Published on 04/29/2026 at 23:58, 5 hours 6 minutes ago

Roxmore Announces Filing of Meeting Materials for Upcoming Shareholders Meeting

View all ACCESSWIRE

EQS Group

Published on 04/30/2026 at 03:05, 1 hour 59 minutes ago

Cohen & Steers Renames UCITS Preferred Securities Strategies as Hybrid Credit Strategies
Published on 04/29/2026 at 23:42, 5 hours 22 minutes ago

H2APEX publishes figures for the 2025 financial year and provides positive outlook
Published on 04/29/2026 at 23:01, 6 hours 3 minutes ago

Sirma Delivers 31% Revenue Growth in 2025 and Advances AI Platform Strategy
Published on 04/29/2026 at 22:15, 6 hours 49 minutes ago

Amrize Grows Revenue 4.7% in First Quarter and Reaffirms 2026 Guidance
Published on 04/29/2026 at 22:05, 6 hours 59 minutes ago

Evotec Announces New Nomination to Board of Directors

Les Echos

Published on 04/29/2026 at 23:00, 6 hours 4 minutes ago

INFORMATION ON ANNUAL FINANCIAL STATEMENTS
Published on 04/29/2026 at 18:31, 10 hours 33 minutes ago

FIRST QUARTER 2026 TURNOVER
Published on 04/29/2026 at 18:15, 10 hours 49 minutes ago

GUILLEMOT CORPORATION | AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE 2025 ANNUAL FINANCIAL REPORT
Published on 04/29/2026 at 18:10, 10 hours 54 minutes ago

Amemdment of the resolution n8 submitted to the AGM of 30 April 2026
Published on 04/29/2026 at 18:00, 11 hours 4 minutes ago

Availability of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE